發(fā)布時(shí)間：2018-03-16 02:24

  本文選題：非小細(xì)胞肺癌　切入點(diǎn)：毓金方　出處：《黑龍江中醫(yī)藥大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的通過觀察毓金方對(duì)中晚期非小細(xì)胞肺癌痰濕蘊(yùn)肺型患者的中位無(wú)進(jìn)展生存期、腫瘤標(biāo)志物CEA、CA125、CA724水平的影響,以探討毓金方對(duì)中晚期非小細(xì)胞肺癌痰濕蘊(yùn)肺型患者的治療效果。方法將2015年9月至2016年4月在黑龍江中醫(yī)藥大學(xué)附屬第一醫(yī)院腫瘤科病房治療并符合納入標(biāo)準(zhǔn)的中晚期非小細(xì)胞肺癌痰濕蘊(yùn)肺型的患者60例,隨機(jī)分為兩組,每組30例。所有患者均被病理確診。試驗(yàn)組口服毓金方聯(lián)合靜脈滴注康萊特注射液,具體用藥方法為毓金方每日1劑,水煎汁300ml,分作2袋,患者分別于早餐前、晚睡前2小時(shí)溫服,1袋/次,2次/日,連服3周,休息1周,靜脈滴注康萊特注射液200ml/次,1次/日,連續(xù)靜脈滴注3周,休息1周,毓金方與康萊特用藥均以28天為1周期,連續(xù)治療6周期;對(duì)照組靜脈滴注康萊特注射液,具體用法用量及療程同試驗(yàn)組。每3個(gè)月進(jìn)行復(fù)查和隨訪,觀察和比較兩組患者中位無(wú)進(jìn)展生存期的長(zhǎng)短和腫瘤標(biāo)志物的變化。結(jié)果1.研究顯示,試驗(yàn)組的中位無(wú)進(jìn)展時(shí)間為5.80個(gè)月;對(duì)照組的中位無(wú)進(jìn)展時(shí)間為4.50個(gè)月,P0.05,差異具有統(tǒng)計(jì)學(xué)意義。2.試驗(yàn)組及對(duì)照組血清腫瘤標(biāo)志物CEA、CA125、CA724水平均呈現(xiàn)逐漸下降趨勢(shì),在治療后第3個(gè)月、6個(gè)月、9個(gè)月治療組CEA、CA724水平比對(duì)照組下降程度明顯,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。3.治療3個(gè)月后,試驗(yàn)組的血清CA125水平比對(duì)照組下降程度未見明顯差異,P0.05,不具有統(tǒng)計(jì)學(xué)意義。4.在治療后第6個(gè)月、9個(gè)月試驗(yàn)組血清CA125水平比對(duì)照組下降程度有明顯差異,具有統(tǒng)計(jì)學(xué)意義(P0.05)。5.試驗(yàn)組中醫(yī)證候積分在在治療后3個(gè)月與對(duì)照組差異不具有統(tǒng)計(jì)學(xué)意義(P0.05),在治療后6個(gè)月、9個(gè)月,試驗(yàn)組與對(duì)照組中醫(yī)證候積分差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論1.毓金方能延長(zhǎng)中晚期非小細(xì)胞肺癌(痰濕蘊(yùn)肺型)患者的中位無(wú)進(jìn)展生存期;2.毓金方能明顯降低中晚期非小細(xì)胞肺癌(痰濕蘊(yùn)肺型)患者血清腫瘤標(biāo)志物CEA、CA125、CA724表達(dá)水平;3.毓金方能夠有效改善中晚期非小細(xì)胞肺癌(痰濕蘊(yùn)肺型)患者的臨床癥狀,降低中醫(yī)證候積分。
[Abstract]:Objective to observe the effect of Yujin recipe on the median progressive survival time and the level of tumor marker CEA CA125 and CA724 in patients with middle and late stage non-small cell lung cancer with phlegm-dampness accumulation. To explore the therapeutic effect of Yujin recipe on the patients with lung type of phlegm dampness accumulation in middle and advanced non-small cell lung cancer. Methods from September 2015 to April 2016, the treatment was carried out in the oncology ward of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine and was in accordance with the standard of inclusion. A total of 60 patients with advanced non-small cell lung cancer with phlegm dampness and lung type, The patients were divided into two groups randomly, 30 cases in each group. All the patients were confirmed by pathology. In the experimental group, Yujin prescription was given orally and Kanglaite injection was given intravenously. The specific methods were Yujin prescription once a day, decoction juice 300ml, divided into 2 bags, the patients were divided into two bags before breakfast. Two hours before bedtime, warm clothes (1 bag / second time / day), continuous administration for 3 weeks, rest for 1 week, intravenous drip of Kanglaite injection 200ml / times per day, continuous intravenous drip for 3 weeks, rest for 1 week. Both Yujin Fang and Kanglaite were given 28 days as one cycle. The control group received intravenous drip of Kanglaite injection, the dosage and course of treatment were the same as the experimental group. The median progression-free survival time and the changes of tumor markers were observed and compared between the two groups. Results 1.The study showed that the median progression-free time was 5.80 months in the trial group. The median time of no progression in the control group was 4.50 months (P 0.05), the difference was statistically significant. 2. The level of serum tumor marker CEACA125 CA724 in the experimental group and control group showed a decreasing trend. After 3 months, 6 months and 9 months of treatment, the level of CEA CA724 in the treatment group was significantly lower than that in the control group, and the difference was statistically significant (P < 0.05). There was no significant difference in the level of serum CA125 between the test group and the control group (P 0.05). There was no significant difference in the level of serum CA125 between the test group and the control group at the 6th month and the 9th month after treatment, and there was a significant difference in the level of serum CA125 between the test group and the control group. The scores of TCM syndromes in the test group were not significantly different from those in the control group in 3 months after treatment, but in 6 months and 9 months after treatment. The difference of TCM syndromes integral between the test group and the control group is statistically significant (P 0.05). Conclusion 1.Yujin prescription can prolong the median progression-free survival time of patients with intermediate and advanced non-small cell lung cancer (phlegm-dampness accumulation lung type) 2.Yujin prescription can obviously reduce the middle and late stage of lung cancer. The expression level of serum tumor marker CEACA125 and CA724 in patients with stage non-small cell lung cancer (phlegm-dampness accumulation lung type). Yujin prescription can effectively improve the clinical symptoms of patients with intermediate and advanced non-small cell lung cancer (phlegm-dampness accumulation lung type). Reduce the integral of TCM syndromes.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R273

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 李雪飛;江洪;;橙皮苷藥理學(xué)作用機(jī)制及研究進(jìn)展[J];海南醫(yī)學(xué);2016年14期

2 張帥;劉勝;;中藥蛇莓的藥理作用和臨床應(yīng)用研究進(jìn)展[J];云南中醫(yī)中藥雜志;2016年06期

3 楊鵬飛;楚世峰;陳乃宏;;黨參的藥理學(xué)研究進(jìn)展及其抗腦缺血再灌注損傷的機(jī)制[J];湖南中醫(yī)藥大學(xué)學(xué)報(bào);2015年12期

4 游昕;熊大國(guó);郭志斌;商友劍;;茯苓多種化學(xué)成分及藥理作用的研究進(jìn)展[J];安徽農(nóng)業(yè)科學(xué);2015年02期

5 仝自強(qiáng);;肺癌放射治療的研究進(jìn)展[J];中國(guó)衛(wèi)生產(chǎn)業(yè);2014年24期

6 余平;許翔鴻;張朝鳳;張勉;;藏紫菀化學(xué)成分及藥理作用研究進(jìn)展[J];亞太傳統(tǒng)醫(yī)藥;2014年12期

7 羅光偉;陳建江;;訶子的藥理作用研究進(jìn)展[J];云南中醫(yī)中藥雜志;2012年11期

8 錢健;秦超;殷長(zhǎng)軍;;腫瘤靶向藥物療效及毒性與基因多態(tài)性間相關(guān)性的研究進(jìn)展[J];中國(guó)腫瘤外科雜志;2012年03期

9 孫娟;孟冰雪;趙啟韜;;瓜蔞藥理作用的物質(zhì)基礎(chǔ)研究概況[J];山東中醫(yī)雜志;2012年06期

10 李紅念;梅全喜;張志群;陳宗良;蔣啟明;;龍葵的化學(xué)成分與藥理作用研究進(jìn)展[J];今日藥學(xué);2011年11期

，

本文編號(hào)：1617931